» Articles » PMID: 4251289

Abnormalities of 5-hydroxytryptamine Uptake and Binding by Blood Platelets from Children with Down's Syndrome

Overview
Journal J Physiol
Specialty Physiology
Date 1971 Jan 1
PMID 4251289
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

1. Blood platelets from normal children and children with the trisomy 21 form of Down's syndrome (mongolism) were studied to determine the cause of the well established reduction in platelet 5-HT in the disease.2. Concentrations of endogenous 5-HT in the platelets from mongols were 25.3% of the concentrations found in normal children.3. The net accumulation of 5-HT in the mongol cells was decreased to 52.7% of normal. This reduction was probably due, in part, to a defect in 5-HT transport, because the initial rates of 5-HT uptake at plasma concentrations of 10(-6) and 10(-5)M were significantly slower.4. Experiments on the efflux of 5-HT from mongol platelets loaded with amine showed that the rate of loss was initially 2.6 and later 7.8 times faster than normal.5. Platelet ATP in mongol cells was 26% of normal, and the reduction of ATP and 5-HT was in the molar ratio of 3:1.6. It is considered that the low platelet 5-HT in Down's syndrome is due to a defective 5-HT transport mechanism and impaired 5-HT binding, resulting from a reduction in the essential binding substance, ATP.

Citing Articles

Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

London J, Ndiaye F, Bui L, Souchet B, Daubigney F, Magnan C Mol Neurobiol. 2018; 56(6):3958-3971.

PMID: 30238388 DOI: 10.1007/s12035-018-1323-2.


Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.

London J, Rouch C, Bui L, Assayag E, Souchet B, Daubigney F Mol Neurobiol. 2017; 55(5):3822-3831.

PMID: 28540658 DOI: 10.1007/s12035-017-0591-6.


A study of gamma-aminobutyric acid uptake in normal and Down's syndrome platelets.

Enns L, McCoy E Br J Pharmacol. 1980; 71(2):553-6.

PMID: 6451255 PMC: 2044451. DOI: 10.1111/j.1476-5381.1980.tb10972.x.


Molecular aspects of the imipramine 'receptor'.

Davis A Experientia. 1984; 40(8):783-94.

PMID: 6088274 DOI: 10.1007/BF01951960.


Accumulation of quinidine by human blood platelets: effects on platelet ultrastructure and 5-hydroxytryptamine.

Boullin D, OBrien R Br J Pharmacol. 1971; 42(1):114-26.

PMID: 5580696 PMC: 1666999. DOI: 10.1111/j.1476-5381.1971.tb07091.x.


References
1.
Tu J, ZELLWEGER H . Blood-serotonin deficiency in Down's syndrome. Lancet. 1965; 2(7415):715-6. DOI: 10.1016/s0140-6736(65)90454-x. View

2.
BAZELON M, PAINE R, Coeiw V, Hunt P, Houck J, MAHANAND D . Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. Lancet. 1967; 1(7500):1130-3. DOI: 10.1016/s0140-6736(67)91708-4. View

3.
Holmsen H, Holmsen I, BERNHARDSEN A . Microdetermination of adenosine diphosphate and adenosine triphosphate in plasma with firefly luciferase system. Anal Biochem. 1966; 17(3):456-73. DOI: 10.1016/0003-2697(66)90181-3. View

4.
IRELAND D . Effect of thrombin on the radioactive nucleotides of human washed platelets. Biochem J. 1967; 105(2):857-67. PMC: 1198387. DOI: 10.1042/bj1050857. View

5.
Pletscher A . Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Br J Pharmacol Chemother. 1968; 32(1):1-16. PMC: 1570304. DOI: 10.1111/j.1476-5381.1968.tb00423.x. View